Structure of Astaxanthin
CAS No.: 472-61-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Astaxanthin is a carotenoid pigment found primarily in marine organisms including Haematococcus Pluvialis, shrimp and salmon. It is a potent lipid-soluble antioxidant.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Ozgur, Gunal ; Sahin, Bahadir ; Atasoy, Beste Melek ; Tomruk, Canberk ; Sirin Tomruk, Cansin ; Tavukcu, Hasan Huseyin , et al.
Abstract: The objective of this study was to evaluate the effects of ionizing radiation (iR) on corpus cavernosum and the potential of astaxanthin (AST) in preventing radiation-induced erectile dysfunction (RiED). Male Wistar Albino rats (10–12 week, 250–300 g) were divided-into four groups: sham (SH, n = 8), radiotherapy (RT, n = 8), vehicle-administered (olive oil (OO); RT + OO, n = 12), and astaxanthin (RT + AST, n = 12). The RT-group received 12-Gy prostate-targeted iR. The vehicle-administered (OO) group received iR with daily 1 ml OO via oral gavage, while the AST-group received iR with 50 mg/kg AST dissolved in OO. After the treatment-period (12-week), intracavernosal pressure to mean arterial pressure (ICP/MAP) ratios in the RT [0.28(0.14–0.65)] and OO groups [0.26(0.19–0.64)] were significantly lower than in the SH [0.6(0.43–0.72)] and AST [0.53(0.35–0.64)] groups (p < 0.05). iR caused narrowing of the cavernous sinusoids (RT:95.38 (84.62–110.05) vs SH:132.33 (113.27–155.86), AST:124.44 (112.11–131.97) µm, p < 0.001). Alpha smooth muscle actin (SH:165 (136.25–188.75) vs RT:100 (87.5–112.5), AST:137.5 (107.5–155), p < 0.001), endothelial nitric-oxide synthase (NOS) (SH:127.5 (115–167.5) vs RT:92.5 (81.25–98.75), AST:115 (86.25–128.75), p = 0.002) and neuronal NOS (SH:152.5 (133.75–163.75) vs RT:95 (81.25–103.75), AST:135 (125–140), p < 0.001) were diminished in the RT-group and preserved in the AST-group according to immunohistochemical scoring. Biochemical measurements of the corpus cavernosum revealed that the level of cGMP was significantly higher (93.15 (71.22–103.38) vs 70.8 (65–72.35) pmol/ml) in the AST-group, while lipid peroxidation was significantly higher (32.38 (29.07–36.98) vs 20.14 (17.85–21.04) nmol.mda/g) in the RT-group (p = 0.004, p < 0.001). This trial showed that AST preserved ICP/MAP values and histopathological-biochemical parameters after exposure to iR.
Show More >
CAS No. : | 472-61-7 |
Formula : | C40H52O4 |
M.W : | 596.84 |
SMILES Code : | CC(/C=C/C(C(C)(C)C[C@@H]1O)=C(C)C1=O)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C(C(C)(C)C[C@@H]2O)=C(C)C2=O |
MDL No. : | MFCD00672621 |
InChI Key : | MQZIGYBFDRPAKN-UWFIBFSHSA-N |
Pubchem ID : | 5281224 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
GL261 cells | 10 µM | 72 h | reduced the number of BrdU-positive cells | PMC7551886 |
U251MG cells | 10 µM | 48 h | suppressed cell migration by 21.15 ± 1.84% | PMC7551886 |
Lymphocytes | 70-300 nM | 48 h | To evaluate the effect of astaxanthin on lymphocyte proliferation, results showed that astaxanthin at 300 nM significantly promoted splenic lymphocyte proliferation. | PMC4730289 |
SK-N-SH cells | 0, 50, 100, 200, 400 µM | 72 h | Astaxanthin significantly inhibited the proliferation of SK-N-SH cells in a concentration-dependent manner. | PMC10685499 |
SK-N-SH cells | 200 µM | 24 h | Astaxanthin suppressed the clone formation ability of SK-N-SH cells, and the effect was highest when combined with si-STAT3. | PMC10685499 |
SK-N-SH cells | 200 µM | 24 h | Astaxanthin induced apoptosis in SK-N-SH cells, and the apoptosis rate was highest when combined with si-STAT3. | PMC10685499 |
SK-N-SH cells | 200 µM | 16 h | Astaxanthin suppressed the migration and invasion of SK-N-SH cells, and the effect was best when combined with si-STAT3. | PMC10685499 |
Bone marrow-derived macrophages (BMMs) | 30 µM | 4 days | Astaxanthin inhibited RANKL and M-CSF-induced osteoclast differentiation by suppressing the expression of NFATc1, TRAP, DC-STAMP, and cathepsin K, without cytotoxic effects on BMMs. | PMC5877773 |
Huh7 cells | 1-20 µM | 24 h | To evaluate the effect of astaxanthin on cell viability, results showed that astaxanthin did not exhibit any significant cytotoxicity in concentrations of up to 20 µM in Huh7 cells | PMC4730345 |
PON1-Huh7 cells | 1-20 µM | 48 h | To evaluate the effect of astaxanthin on PON1 enzyme activity, results showed that astaxanthin significantly induced PON1 enzyme activity | PMC4730345 |
HepG2 cells | 1-20 µM | 24 h | To evaluate the effect of astaxanthin on glutathione levels, results showed that astaxanthin dose-dependently increased cellular glutathione levels | PMC4730345 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | Aged mice | Oral | 300 mg/kg | Once daily for 8 weeks | To evaluate the effects of astaxanthin on muscle strength and muscle quality in aged mice. Results showed that the specific force was significantly higher in the astaxanthin-treated group compared to the placebo group. | PMC6204600 |
mice | glioblastoma model | oral | 10 and 30 mg/kg | daily for 10 days | suppressed the glioblastoma progression | PMC7551886 |
C57BL/6 mice | OVA-induced asthma model | Oral | 5, 10, 50 mg/kg | Once daily for 5 days | To investigate the inhibitory effect of astaxanthin on airway inflammation in OVA-induced asthmatic mice. Results showed that astaxanthin significantly inhibited respiratory system resistance, elastance, newtonian resistance, tissue damping, and tissue elastance. It also suppressed the total cell number, IL-4, and IL-5, and increased IFN-γ in BALF. In sera, total IgE, IgG1, and OVA-specific IgG1 levels were reduced, while IgG2a and OVA-specific IgG2a levels were increased. | PMC6150233 |
Mice | Not specified | Oral | 0.28, 1.4 and 7 mg/kg | Once daily for 14 days | To evaluate the effect of astaxanthin on lymphocyte proliferation in mice, results showed that astaxanthin significantly enhanced LPS-induced lymphocyte proliferation. | PMC4730289 |
Mice | Phf7 knockout mice | Oral | 30 mg/kg | Once daily for 4 weeks | To investigate the therapeutic effect of astaxanthin on spermatogenesis defects in Phf7 knockout mice, results showed that astaxanthin significantly increased sperm count and motility, and reduced ROS levels and germ cell apoptosis in the testis | PMC10618686 |
Nude mice | SK-N-SH tumor model | Intragastric administration | 200 mg/kg | Once daily for 4 weeks | Astaxanthin suppressed the growth of SK-N-SH tumors in nude mice, and the effect was highest when combined with si-STAT3. | PMC10685499 |
C3H/HeN female mice | Ovariectomy-induced osteoporosis model | Oral | 5 mg/kg and 10 mg/kg | Once daily for 6 weeks | Oral administration of AST for 6 weeks inhibited the increase in and uterine atrophy in ovariectomized mice, reduced serum levels of calcium, inorganic phosphorus, alkaline phosphatase, and total cholesterol, and suppressed TRAP activity. Additionally, AST improved the bone microarchitecture of the tibia and femur, increased trabecular bone volume and number, and decreased trabecular separation. AST also inhibited the reduction of bone mineral density in the femur and tibia and reduced the number of TRAP-positive cells. | PMC5877773 |
mice | LPS-induced sepsis model | oral | 50, 100, and 200 mg/kg | every 24 hours for 2 days | To evaluate the antioxidant ability of Astaxanthin in LPS-induced mice sepsis model, the results showed that Astaxanthin significantly suppressed NO and ROS production and reduced lipid peroxidation activities. | PMC8540215 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02264938 | Macular Degeneration | Not Applicable | Completed | - | - |
NCT03702374 | Diabetic Retinopathy | Phase 3 | Recruiting | November 1, 2020 | Mexico ... More >> Institute of Experimental and Clinical Therapeutics, Recruiting Guadalajara, Jalisco, Mexico, 44340 Contact: Adolfo D. Rodriguez-Carrizalez, PhD +52 33 10585200 ext 33658 adolfo.rodriguez@academicos.udg.mx Contact: Cecilia Olvera-Montaño, MD +52 33 10 58 52 00 ext 33658 ceciliaom.drcrt@gmail.com Sub-Investigator: Cecilia Olvera-Montaño, MD Sub-Investigator: José A. Castellanos-González, MSc Sub-Investigator: Alejandra G Miranda-Díaz, PhD Less << |
NCT02582424 | Hyperlipidemia | Not Applicable | Completed | - | - |
NCT01323036 | Healthy Volunteers | Not Applicable | Completed | - | Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less << |
NCT02422927 | Atherosclerosis ... More >> Inflammation Hypercholesterolemia Less << | Phase 4 | Completed | - | - |
NCT02969070 | Hypercholesterolemia ... More >> Endothelial Dysfunction Less << | Phase 3 | Unknown | March 2017 | Italy ... More >> University of Naples "Federico II" Recruiting Naples, Italy, 80131 Contact: Giuseppe Giugliano, MD, PhD +390817462240 giuseppe.giugliano@unina.it Sub-Investigator: Raffaele Izzo, MD Sub-Investigator: Maurizio Galderisi, MD Sub-Investigator: Giuseppe Giugliano, MD, PhD Less << |
NCT01562080 | Hyperlipidemia ... More >> Low-density-lipoprotein-type Elevated Triglycerides Less << | Phase 2 Phase 3 | Completed | - | Spain ... More >> Hosp. Universitario San Joan Reus, Tarragona, Spain Less << |
NCT02062034 | Non-proliferative Diabetic Ret... More >>inopathy Diabetes Mellitus Type 2 Less << | Phase 2 | Completed | - | Mexico ... More >> Cardiovascular Research Unit, University of Guadalajara Guadalajara, Jalisco, Mexico, 44340 Less << |
NCT03216811 | Hypercholesterolemia | Phase 2 | Completed | - | Italy ... More >> University Hospital of Ferrara Cona, Ferrara, Italy, 44124 Less << |
NCT03470376 | Hypercholesterolemia ... More >> Inflammation Atherosclerosis Less << | Phase 4 | Completed | - | - |
NCT01087632 | Metabolic Syndrome | Not Applicable | Completed | - | Italy ... More >> Federico II University - Department of Internal Medicine Naples, Italy Less << |
NCT01647984 | Ventricular and Atrial Extrasy... More >>toles Less << | Phase 4 | Completed | - | Italy ... More >> Ambulatorio Ipertensione e Unità Coronarica Federico II University Naples, Italy, 80131 Less << |
NCT02087033 | Arrhythmia | Not Applicable | Unknown | - | Italy ... More >> Policlinico San Pietro Recruiting Ponte San Pietro, Bergamo, Italy, 24100 Contact: flavio doni, MD 0039035604416 flavio.doni@fastwebnet.it Sub-Investigator: flavio doni, MD Policlinico San Donato Recruiting San Donato Milanese, Milan, Italy, 20097 Contact: riccardo cappato, MD 0252774337 riccardo.cappato@grupposandonato.it Sub-Investigator: Cristina Balla, MD Less << |
NCT01167205 | Healthy Overw... More >>eight Obesity Less << | Not Applicable | Unknown | - | Korea, Republic of ... More >> Clinical Research Institute Seoul National University Hospital Not yet recruiting Seoul, Korea, Republic of, 110-744 Contact: Wan Gyoon Shin, Ph D, Pharm D +82 2 740 85556 wgshin@snu.ac.kr Less << |
NCT01241877 | Athletic Performance | Not Applicable | Unknown | - | Netherlands ... More >> Maastricht University Recruiting Maastricht, LI, Netherlands, 6229 Contact: Peter Res, MSc +3143381383 peter.res@maastrichtuniversity.nl Less << |
NCT03460860 | Skin Aging Wr... More >>inkles Less << | Not Applicable | Recruiting | September 7, 2018 | Philippines ... More >> PDC Building, 1440 Taft Avenue Recruiting Manila, Metro Manila, Philippines Contact: Nenita Alberto, MD (632) 5232519 albertonenita@yahoo.com Less << |
NCT02343497 | Dyslipidemias | Not Applicable | Completed | - | France ... More >> Centre Nutrition Clinique Naturalpha Lille, France, 59020 Less << |
NCT03443882 | Healthy Volunteers | Early Phase 1 | Active, not recruiting | September 25, 2018 | Israel ... More >> Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel Hashomer, Israel, 52621 Less << |
NCT02373111 | Ageing Photo-... More >>aging Less << | Not Applicable | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of, 110744 Less << |
NCT02310087 | Infertility, Male | Not Applicable | Recruiting | December 2019 | Slovenia ... More >> Division of Ob/Gyn, University Medical Centre Ljubljana Recruiting Ljubljana, Slovenia, 1000 Contact: Bojana Pinter, MD, PhD +386-41-718-923 bojana.pinter@kclj.si Contact: Senka Imamovic Kumalic, MD +386-40-614-904 senka81@gmail.com Less << |
NCT03368872 | Sarcopenia | Not Applicable | Completed | - | United States, Washington ... More >> Fred Hutchinson Cancer Research Center Prevention Center Seattle, Washington, United States, 98109 University of Washington Medical Center Seattle, Washington, United States, 98195 Less << |
NCT03209895 | Joint Pain | Not Applicable | Completed | - | United States, California ... More >> 1621 Bridgeway Sausalito, California, United States, 94965 Less << |
NCT02088242 | Body Temperature Regulation | Not Applicable | Unknown | August 2015 | Israel ... More >> Sheba medical center Not yet recruiting Tel-Hashomer, Ramat- Gan, Israel Contact: Ofir Frenkel, M.D +972529243399 Ofir.Frenkel@sheba.health.gov.il Principal Investigator: Ofir Frenkel, M.D Less << |
NCT03310359 | Metabolic Syndrome X | Phase 1 | Recruiting | April 2018 | United States, California ... More >> Altman Clinical and Translational Research Institute (ACTRI) Recruiting San Diego, California, United States, 92037 Contact: Adrienne Armstrong, BA 858-646-2884 a3armstrong@ucsd.edu Sub-Investigator: Sunder Mudaliar, MD Sub-Investigator: Jeremy Pettus, MD Less << |
NCT03664466 | Osteoarthritis, Knee | Not Applicable | Not yet recruiting | December 2019 | - |
NCT02397811 | Bioavailability of Astaxanthin... More >> Formulations Less << | Not Applicable | Completed | - | United States, Florida ... More >> USF Health: College of Medicine Tampa, Florida, United States, 33612 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.68mL 0.34mL 0.17mL |
8.38mL 1.68mL 0.84mL |
16.75mL 3.35mL 1.68mL |
|
Dissolving Methods |
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|